scholarly journals Diagnosis and Management of Female Pattern Hair Loss

2020 ◽  
Vol 4 (1) ◽  
pp. 29-47
Author(s):  
Sarah Diba ◽  
Maria Mayfinna Gozali ◽  
Yuli Kurniawati
Keyword(s):  
Hair Loss ◽  
Clinical Manifestations ◽  
Term Treatment ◽  
Hair Follicles ◽  
Low Level Laser Therapy ◽  
Female Pattern Hair Loss ◽  
Level Laser ◽  
Long Term Treatment ◽  
Topical Minoxidil

Abstract Female pattern hair loss (FPHL) is the most common hair loss in post-puberty female. Prevalence of this nonscarring alopecia increases with age.  The etiology of FPHL is still unclear, but hormonal and genetic factors are associated with pathogenesis of FPHL. Hormonal factor in FPHL is not as strong as in male pattern hair loss (MPHL). Clinical manifestations of FPHL are characterized by nonscarring baldness with shortening anagen phases and miniaturization of hair follicles, predominantly occur at the vertex, middle, and frontal regions. Hair shedding occurs progressively. The diagnosis of FPHL is established based on clinically. Classification of FPHL is according to Ludwig's criteria. Current FDA-approved FPHL therapy is topical minoxidil 2%, hair transplantation, and low level laser therapy (LLLT). Anti-androgen therapy still needs to be investigated further. The prognosis of FPHL is poor because the progressiveness continues with age. Long term treatment required for FPHL because it is a chronic residif disease. The treatment only prevents the progression of hair loss and does not cure. 

Effects of methylthiouracil treatment on the growth and moult of cashmere fibre in goats

1996 ◽  
Vol 62 (3) ◽  
pp. 513-520 ◽  
Author(s):  
S. M. Rhind ◽  
S. R. McMillen
Keyword(s):  
Fibre Diameter ◽  
Live Weight ◽  
Term Treatment ◽  
Hair Follicles ◽  
Long Term Treatment ◽  
Fibre Growth ◽  
The Mean ◽  
Secondary Fibre

AbstractThe effect of long-term treatment of goats with methylthiouracil on the timing, amount and quality of secondary fibre (cashmere) growth and timing of cashmere moult in goats was investigated. From early June, groups of 10 Icelandic × Scottish feral goats were dosed orally each day, for a 15-month period, with 5 mg methylthiouracil per kg live weight in 30 ml water (treated; T) or with water only (control; C). Treatment with methylthiouracil resulted in a significant reduction (P < 0·05) in the proportion of active secondary hair follicles present during March. This was associated with a delayed onset of moult of cashmere in T compared with C goats at both the head (11 March v. 23 February; s.e. 3·33 days; P< 0·05) and mid side (27 March v. 26 February; s.e. 3·58 days; P < 0·001). There was no effect on the time of onset (C, 19 July; T, 19 July; s.e. 5·84 days) or cessation of cashmere fibre growth (C, 9 December; T, 8 December; s.e. 1·69 days) or the mean growth rate (C, 0·473 mm/day; T, 0·451 mm/day; s.e. 0·025) and fibre diameter (C, 16·9 μm; T, 15·4 jim; s.e. 0·266). Wlien present in the fleece, the mean weight and proportion of cashmere was higher in C than in T goats (P < 0·05). It is concluded that methylthiouracil treatment altered secondary follicle activity and the time of onset of the moult of cashmere and that these changes may be a result of reduced triiodothyronine production from thyroxine and associated secondary changes in profiles of insulin and IGF-1.

scholarly journals The Female Pattern Hair Loss: Review of Etiopathogenesis and Diagnosis

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Anja Vujovic ◽  
Véronique Del Marmol
Keyword(s):  
Hair Loss ◽  
Current Knowledge ◽  
Diagnostic Testing ◽  
Clinical Manifestations ◽  
Hair Follicles ◽  
Hair Density ◽  
Female Pattern Hair Loss ◽  
Significant Impairment ◽  
Pattern Distribution

Female pattern hair loss (FPHL) is the most common hair loss disorder in women. Initial signs may develop during teenage years leading to a progressive hair loss with a characteristic pattern distribution. The condition is characterized by progressive replacement of terminal hair follicles over the frontal and vertex regions by miniaturized follicles, that leads progressively to a visible reduction in hair density. Women diagnosed with FPHL may undergo significant impairment of quality of life. FPHL diagnosis is mostly clinical. Depending on patient history and clinical evaluation, further diagnostic testing may be useful. The purpose of the paper is to review the current knowledge about epidemiology, pathogenesis, clinical manifestations, and diagnosis of FPHL.

Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort

2020 ◽  
pp. jmedgenet-2020-107162
Author(s):  
Grigoris Effraimidis ◽  
Ulla Feldt-Rasmussen ◽  
Åse Krogh Rasmussen ◽  
Pamela Lavoie ◽  
Mona Abaoui ◽  
...  
Keyword(s):  
Fabry Disease ◽  
Clinical Manifestations ◽  
Term Treatment ◽  
Agalsidase Beta ◽  
Deletion Mutations ◽  
Agalsidase Alfa ◽  
Long Term Treatment ◽  
High Risk Screening

IntroductionRecent studies showed the usefulness of globotriaosylsphingosine (lyso-Gb3) and related analogues, deacylated forms of globotriaosylceramide (Gb3), for high-risk screening, treatment monitoring and follow-up for patients with Fabry disease.MethodsWe evaluated Gb3, lyso-Gb3 and analogues using tandem mass spectrometry in 57 women with Fabry disease followed during a period of 15.4 years. Twenty-one women were never treated and 36 received treatment (agalsidase-beta, n=30; agalsidase-alfa, n=5; or migalastat, n=1). Lyso-Gb3 and analogues at m/z (−28), (−2), (+16), (+34) and (+50) were analysed in plasma and urine. Total Gb3 and lyso-Gb3 analogues at m/z (−12) and (+14) were evaluated in urine while the analogue at m/z (+18) was evaluated in plasma.ResultsA strong correlation between plasma and urine lyso-Gb3 and analogue levels was revealed. Plasma and urine lyso-Gb3 and analogue levels were not statistically different between patients carrying missense (n=49), nonsense (n=6) or deletion mutations (n=2). Never treated patients had lower plasma lyso-Gb3 and analogues at m/z (−28), (−2), (+16), (+34) and the seven urinary lyso-Gb3 analogues compared with pretreatment levels of the treated patients. A significant reduction of plasma lyso-Gb3 and five analogues, as well as urine Gb3 and six lyso-Gb3 analogues, but not lyso-Gb3 and lyso-Gb3 at m/z (+50), was observed post-treatment with agalsidase-beta. The same tendency was observed with agalsidase-alfa.ConclusionWomen with Fabry disease who started treatment based on clinical manifestations had higher lyso-Gb3 and analogue biomarker levels than never treated women. This indicates that a biomarker cut-off could potentially be a decision tool for treatment initiation in women with Fabry disease.

Medicinal Plants for the Treatment of Hair Loss and the Suggested Mechanisms

2018 ◽  
Vol 24 (26) ◽  
pp. 3090-3100 ◽  
Author(s):  
Yu-Li Shen ◽  
Xiao-Qin Li ◽  
Rong-Rong Pan ◽  
Wei Yue ◽  
Li-Jun Zhang ◽  
...  
Keyword(s):  
Side Effects ◽  
Medicinal Plants ◽  
Hair Loss ◽  
Term Treatment ◽  
Androgenic Alopecia ◽  
New Agents ◽  
Long Term Treatment ◽  
Life Threatening

Hair loss may not be recognized as a life-threatening disorder. However, it has a great harm to a person’s self-respect, mental health, and entirety quality of life. Androgenic alopecia (AGA) is the most common type of hair loss, which affects a great number of both men and women. Alopecia can be treated with various hair loss strategies, including hair transplant, cosmetics and medication. Medical treatment shows the outstanding ability in improving hair growth. Plenty of drugs prevents alopecia by inhibiting the secretion of male hormone. But these medicines exhibit some undesirable side effects. Since hair loss requires a long-term treatment and minimizing adverse side effects is extremely urgent in drug development. Accordingly, new agents are obtained from natural products with less adverse effects. Traditional Chinese medicines exhibit unique advantages in hair loss treatment. This review generalizes and analyzes the recent progress of medicinal plants for the treatment of hair loss, suggested mechanisms and outlines a number of trials taken or underway to optimize the treatment.

scholarly journals Examining the Safety and Efficacy of Low-Level Laser Therapy for Male and Female Pattern Hair Loss: A Review of the Literature

2020 ◽  
Vol 6 (5) ◽  
pp. 259-267
Author(s):  
Andjela Egger ◽  
Sydney R. Resnik ◽  
Divya Aickara ◽  
Eric Maranda ◽  
Michael Kaiser ◽  
...  
Keyword(s):  
Laser Therapy ◽  
Hair Loss ◽  
Low Level Laser Therapy ◽  
Review Of The Literature ◽  
Male And Female ◽  
Safety And Efficacy ◽  
Low Level ◽  
Low Level Laser ◽  
Female Pattern Hair Loss ◽  
Level Laser

scholarly journals Beyond the adrenals: Organ manifestations in inherited primary adrenal insufficiency in children

2020 ◽  
Vol 182 (3) ◽  
pp. C9-C12
Author(s):  
Clemens Kamrath
Keyword(s):  
Adrenal Insufficiency ◽  
Bone Growth ◽  
Pediatric Population ◽  
Clinical Manifestations ◽  
Term Treatment ◽  
Primary Adrenal Insufficiency ◽  
Long Term Treatment ◽  
Wide Range ◽  
Organ Manifestations

Primary adrenal insufficiency (PAI) in children is mostly due to genetic defects. The understanding of the molecular genetics of the causes of adrenal insufficiency in the pediatric population has made significant progress during the last years. It has been shown that inherited PAI can lead to certain clinical manifestations and health problems in children beyond the adrenals. Organ dysfunctions associated with different forms of PAI in children include a wide range of organs such as gonads, brain, heart, bone, growth, bone marrow, kidney, skin, parathyroid, and thyroid. Diagnosing the correct genetic cause of PAI in children is therefore crucial to adequately control long-term treatment and follow-up in such patients.

Sign in / Sign up

Export Citation Format

Share Document